Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?

NCT06922656 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Type 1 Diabetes

Interventions

DRUG: Dapagliflozin (DAPA)
DRUG: Pioglitazone 45 mg
DRUG: Placebo

Sponsor

Dasman Diabetes Institute